Brief: Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis For Ampion Targeting Severe Osteoarthritis Of The Knee (Oak)

Ampio Pharmaceuticals

02/03/2022 21:36

March 2 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO PHARMACEUTICALS, INC. RELEASES POSITIVE PHASE 3 DATA
ANALYSIS FOR AMPION™ TARGETING SEVERE OSTEOARTHRITIS OF THE KNEE
(OAK)
    * AMPIO PHARMACEUTICALS INC - COMPLETE ANALYSIS OF AP-013
DATA
SHOW AMPION REDUCED PAIN WITH STATISTICAL SIGNIFICANCE
    * AMPIO PHARMACEUTICALS INC - U.S. FOOD AND DRUG
ADMINISTRATION
HAS CONFIRMED AMPIO'S TYPE C MEETING REQUEST
    * AMPIO PHARMACEUTICALS INC - SENSITIVITY ANALYSIS FOUND A
STATISTICALLY SIGNIFICANT IMPACT FROM COVID-19, AND AS SPECIFIED
IN OUR STUDY PLAN

Source text for Eikon:  ID:nPn4gklkPa 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))